MedTrace Logo

A Study Testing the Safety and Effects of FB102 in Healthy Volunteers

NCT07623057 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-08-19

No results posted yet for this study

Summary

The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.

Conditions

  • Healthy Volunteer

Interventions

DRUG

FB102 Single dose

FB102 will be administered as a single dose

DRUG

FB102 Multiple doses

FB102 will be administered once weekly for 4 doses.

DRUG

FB102 Placebo

Matching placebo identical to FB102 formulation but without the active pharmaceutical ingredient

Sponsors & Collaborators

  • Forte Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Indika P Leelasena · University of the sunshine coast clinical trials, Morayfield

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-23
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07623057 on ClinicalTrials.gov